JP MORGAN/CALL/BRISTOL-MYERS SQUIBB/75/0.1/17.01.25

JP MORGAN/CALL/BRISTOL-MYERS SQUIBB/75/0.1/17.01.25 Stock

DE000JS7PU57

Market Closed - Börse Stuttgart 05:41:27 2024-05-31 EDT
0.004 ^EUR	+33.33%

1 month	-42.86%
3 months	-80.95%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart BRISTOL-MYERS SQUIBB COMPANY

Chart JP MORGAN/CALL/BRISTOL-MYERS SQUIBB/75/0.1/17.01.25

Latest news about BRISTOL-MYERS SQUIBB COMPANY

KRAZATI (adagrasib) Demonstrated Statistically Significant Improvement in Progression-Free Survival in Patients with Pretreated Locally Advanced or Metastatic KRASG12C-Mutated Non-Small Cell Lung Cancer	06-01	BU
Bristol-Myers Squibb Says Breyanzi Gets FDA Approval as CAR T Cell Therapy for Mantle Cell Lymphoma	05-30	MT
Bristol Myers: FDA approval for Breyanzi	05-30	CF
US FDA allows use of Bristol's cell therapy for rare blood cancer	05-30	RE

More news

Quotes 5-day view

Date	Price	Change
24-05-31	0.004	+33.33%
24-05-30	0.003	-25.00%
24-05-29	0.004	-20.00%
24-05-28	0.005	-.--%
24-05-27	0.005	-.--%

Delayed Quote Börse Stuttgart

Last update May 31, 2024 at 05:41 am

More quotes

Static data

Product type	Warrants
Buy / Sell	CALL
Underlying	BRISTOL-MYERS SQUIBB COMPANY
Issuer	J.P. Morgan
WKN	JS7PU5
ISIN	DE000JS7PU57
Date issued	2023-02-10
Strike	75 $
Maturity	2025-01-17 (230 Days)
Parity	10 : 1
Emission price	0.92 €
Emission volume	N/A
Settlement	règlement en espèces
Currency	EUR

Technical Indicators

Highest since issue	0.87 €
Lowest since issue	0.003 €
Delta	0.03x
Omega	9.247
Premium	82.7x
Gearing	303.23x
Moneyness	0.5483
Difference Strike	33.88 $
Difference Strike %	+45.17%
Spread	0.015 €
Spread %	75.00%
Theoretical value	0.0125
Implied Volatility	37.99 %
Total Loss Probability	98.49 %
Intrinsic value	0.000000
Present value	0.0125
Break even	75.14 €
Theta	-0x
Vega	0x
Rho	0x

Company Profile

Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques. The United States account for 70.1% of net sales.

Sector

More about the company

Ratings for Bristol-Myers Squibb Company

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Consensus: Bristol-Myers Squibb Company

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

41.09 USD

Average target price

53.19 USD

Spread / Average Target

+29.46%

Consensus